Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Spdr S&P Biotech Etf XBI

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the S&P Biotechnology Select Industry Index derived from the biotechnology segment of a U. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the index), the fund employs a sampling strategy. It generally invests... see more

Recent & Breaking News (ARCA:XBI)

This Biotech Name Could Be Best In Breed For 2017

Benzinga.com  June 13, 2017

Trump: Drug Industry Is 'Getting Away With Murder'

Benzinga.com  January 11, 2017

The Things You Need To Know Ahead Of Mylan's Q3 Earnings

Benzinga.com  November 9, 2016

Last Night's Election - A Series Of Fortunate Events For Big Pharma

Benzinga.com  November 9, 2016

Biotech Is Getting A Big Boost Following Clinton's Loss

Benzinga.com  November 9, 2016

Scott Bauer's SPDR S&P Biotech ETF Trade

Benzinga.com  October 7, 2016

Biotechs Are Getting Crushed After Clinton And The White House Trash EpiPen Price Hike

Benzinga.com  August 24, 2016

Juno Therapeutics Plunges 30% After 2 Patient Deaths From Lead Cancer Drug

Benzinga.com  July 7, 2016

Traders Get It Right (Sort Of) With Leveraged Biotech ETFs

Benzinga.com  June 22, 2016

Biotechs Are Ripping Following IPAB Ruling

Benzinga.com  June 22, 2016

This Biotech ETF Could Be Ready To Party

Benzinga.com  May 27, 2016

Return Of The Mack: This Biotech ETF Is Back

Benzinga.com  April 19, 2016

A Leader-Laggard Long-Short ETF Pair Trade

Benzinga.com  April 7, 2016

Inklings Of Upside For A Leveraged Biotech ETF

Benzinga.com  April 6, 2016

Some Traders Aren't Shy About Betting On A Biotech Rebound

Benzinga.com  February 19, 2016

This Biotech ETF Is Setting A Blistering Pace

Benzinga.com  February 11, 2016

Joe McCann: Here's How To Play Biotech Market In Earnings Season

Benzinga.com  February 3, 2016

Even With Volatility, Investors Love Biotech ETFs

Benzinga.com  January 22, 2016

Betting On A Biotech Bounce With A Familiar ETF

Benzinga.com  January 12, 2016

Another Visit With A Leveraged Biotech ETF

Benzinga.com  December 1, 2015